Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $13.11 $15.83 Friday, 10th May 2024 SRRK stock ended at $13.35. This is 8.25% less than the trading day before Thursday, 9th May 2024. During the day the stock fluctuated 8.97% from a day low at $13.19 to a day high of $14.37.
90 days $12.81 $17.90
52 weeks $5.56 $21.17

Historical Scholar Rock Holding Corp. prices

Date Open High Low Close Volume
Jan 24, 2024 $15.06 $15.41 $14.63 $14.74 649 895
Jan 23, 2024 $15.56 $15.79 $14.50 $14.73 703 269
Jan 22, 2024 $15.13 $15.99 $15.13 $15.39 774 926
Jan 19, 2024 $15.85 $16.24 $14.92 $15.06 680 216
Jan 18, 2024 $15.75 $15.99 $15.26 $15.87 615 123
Jan 17, 2024 $15.82 $16.10 $15.51 $15.59 540 542
Jan 16, 2024 $16.33 $16.33 $15.66 $15.91 489 870
Jan 12, 2024 $16.11 $16.46 $15.56 $16.33 526 684
Jan 11, 2024 $16.36 $16.49 $15.73 $15.90 748 235
Jan 10, 2024 $16.19 $16.71 $16.01 $16.60 706 332
Jan 09, 2024 $16.88 $17.09 $16.15 $16.25 394 971
Jan 08, 2024 $16.00 $17.10 $15.57 $17.08 758 354
Jan 05, 2024 $16.75 $16.85 $15.35 $16.14 1 203 581
Jan 04, 2024 $17.17 $17.58 $16.81 $17.10 801 055
Jan 03, 2024 $17.38 $17.56 $16.44 $16.64 865 102
Jan 02, 2024 $18.49 $18.89 $17.43 $17.50 811 258
Dec 29, 2023 $20.30 $20.30 $18.11 $18.80 1 506 617
Dec 28, 2023 $19.43 $21.17 $19.30 $20.32 2 190 446
Dec 27, 2023 $19.38 $19.45 $18.78 $19.31 786 396
Dec 26, 2023 $19.12 $19.48 $18.48 $19.19 588 222
Dec 22, 2023 $18.49 $19.20 $18.41 $18.75 1 132 505
Dec 21, 2023 $18.19 $18.64 $17.86 $18.00 673 261
Dec 20, 2023 $18.74 $19.31 $17.65 $17.75 1 080 942
Dec 19, 2023 $18.28 $19.46 $18.13 $18.90 1 307 483
Dec 18, 2023 $18.76 $18.97 $17.89 $17.95 825 154
Click to get the best stock tips daily for free!

About Scholar Rock Holding Corp.

Scholar Rock Holding . Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical tria... SRRK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT